|Trade names||Cinol Forte, Cinol Plus, Depten-OZ, M-Olan Plus, Oladay-F, Olanex-F, Olapin Forte, Olapin Plus, Olorest-F, Symbyax|
|Pregnancy cat.||C (AU) C (US)|
|Legal status||℞-only (US) not controlled|
| (what is this?)
The drug combination olanzapine/fluoxetine (trade name Symbyax, created by Eli Lilly and Company) is a single capsule containing the atypical antipsychotic olanzapine and the selective serotonin reuptake inhibitor (SSRI) fluoxetine. Olanzapine/fluoxetine is primarily used to treat the depressive episodes of bipolar I disorder as well as treatment-resistant depression.
Olanzapine/fluoxetine was approved by the U.S. Food and Drug Administration (FDA) to treat the depressive episodes of bipolar I disorder in 2003. In 2009, it was granted approval for the treatment of treatment-resistant depression.
Olanzapine/fluoxetine, or other antidepressant/antipsychotic combinations, are sometimes prescribed off-label for anxiety disorders, eating disorders, obsessive–compulsive disorder (OCD), and posttraumatic stress disorder (PTSD).
Olanzapine/fluoxetine is available as a capsule. Currently, five dosage combinations are produced (measured in mg olanzapine/mg fluoxetine): 3 mg/25 mg, 6 mg/25 mg, 6 mg/50 mg, 12 mg/25 mg, 12 mg/50 mg.
Possible side effects of olanzapine/fluoxetine include all those of the two component drugs: olanzapine and fluoxetine. Common side effects include suicidal thoughts, increased appetite, weight gain, drowsiness, fatigue, dry mouth, swelling, tremor, blurred vision and difficulty concentrating.
Olanzapine/fluoxetine could produce a severe allergic reaction and should not be used if the patient has previously experienced an allergic reaction to either fluoxetine or olanzapine.
Like other SSRIs, olanzapine/fluoxetine carries a black box warning stating that it could increase the risk of suicide in patients ages 24 and under. The warning also states that olanzapine/fluoxetine may increase the risk of death in elderly patients with dementia-related psychosis.
- Symbyax Prescribing Information. Eli Lilly and Company. 2010. http://pi.lilly.com/us/symbyax-pi.pdf
- Grohol, J. "FDA Approves Symbyax for Treatment Resistant Depression." Psych Central. http://psychcentral.com/blog/archives/2009/03/23/fda-approves-symbyax-for-treatment-resistant-depression/
- McIntyre R, Katzman M. (2003). "The role of atypical antipsychotics in bipolar depression and anxiety disorders.". Bipolar Disord. 5 Suppl 2: 20–35. PMID 14700010.
- Pederson KJ, Roerig JL, Mitchell JE. (2003). "Towards the pharmacotherapy of eating disorders". Expert Opin Pharmacother. 4 (10): 1659–78. doi:10.1517/146565220.127.116.119. PMID 14521477.
- Koran LM, Ringold AL, Elliott MA. (2000). "Olanzapine augmentation for treatment-resistant obsessive-compulsive disorder". J Clin Psychiatry. 61 (7): 514–7. doi:10.4088/JCP.v61n0709. PMID 10937610.
- Stein MB, Kline NA, Matloff JL. (2003). "Adjunctive olanzapine for SSRI-resistant combat-related PTSD: a double-blind, placebo-controlled study". Am J Psychiatry. 159 (10): 1777–9. PMID 12359687.
- Drugs.com http://www.drugs.com/pdr/symbyax.html